Current therapies and emerging drugs in the pipeline for type 2 diabetes.
Quang T. Nguyen, Raymond A Plodkowski(University of California San Diego), Loida Nguyen(University of Nevada, Reno), Karmella T. Thomas(University of Nevada, Reno), Katie B Lyons(University of Nevada, Reno)
Europe PMC (PubMed Central)
September 1, 2011
Cited by 6
Related Papers
American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity
|Endocrine Practice|2016|1.8k
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2010|1k
Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
|Diabetes Care|2013|494